Xenellis John, Papadimitriou Nikolaos, Nikolopoulos Thomas, Maragoudakis Paulos, Segas John, Tzagaroulakis Antonios, Ferekidis Eleutherios
Department of Otolaryngology, School of Medicine, University of Athens, "Hippokration" Hospital, Athens, Greece.
Otolaryngol Head Neck Surg. 2006 Jun;134(6):940-5. doi: 10.1016/j.otohns.2005.03.081.
Although systemic steroids in sudden sensorineural hearing loss (SSHL) appears to be the most effective and the most widely accepted treatment today, a significant number of patients do not respond to steroid treatment or they cannot receive steroids for medical reasons. Intratympanic (IT) administration of steroids appears to be an alternative or additional method of management without the side effects of intravenous steroids. The aim of this study is to investigate the effectiveness and safeness of IT administration of steroids in patients who had not responded to IV treatment and to compare treatment efficacy with controls.
Our study consisted of 37 patients with SSHL who, at the end of 10 days of therapy with intravenous steroids as a 1st line treatment, had pure-tone 4-frequency (0.5, 1, 2, and 4 kHz) average (PTA) of worse than 30 dB or worse than 10 dB from the contralateral ear (defined as failed intravenous treatment). They were randomized into 2 groups, treatment and control. The 19 patients of the treatment group received approximately 0.5 mL sterile aqueous suspension of methylprednisolone acetate in a concentration of 80 mg/2 mL by direct injection. The procedure was carried out 4 times within a 15-day period. An audiogram was performed before each injection and approximately 1.5 months after the last session.
All patients tolerated the procedure well. No perforation or infection was noticed in any of the patients at their last visit. With regard to the 19 patients who received intratympanic treatment, in 9 patients, the PTA threshold improved more than 10 db, in 10 patients there was no change greater than 10 db, and no patients deteriorated more than 10 db. In the control group, none of the patients showed any change greater than 10 db. The difference was statistically significant (P = 0.002). The treatment group showed an improvement in mean PTA of 14.9 dB, whereas the control group showed a deterioration of 0.8 dB, and this difference also was statistically significant (P = 0.0005). IT treatment (P = 0.0001), better post-IV PTA (P = 0.0008), and absence of vertigo (P = 0.02) were good predictors of the outcome. In contrast, sex, age, affected ear, days to admission, and pattern of the initial audiogram showed no significant influence on the outcome.
IT steroid administration after failed intravenous steroids is a safe and effective treatment in sudden sensorineural hearing loss.
尽管全身使用类固醇治疗突发性感音神经性听力损失(SSHL)似乎是目前最有效且被广泛接受的治疗方法,但仍有相当数量的患者对类固醇治疗无反应,或者因医学原因无法接受类固醇治疗。鼓室内(IT)注射类固醇似乎是一种替代或辅助治疗方法,且无静脉注射类固醇的副作用。本研究的目的是调查鼓室内注射类固醇对静脉治疗无效患者的有效性和安全性,并与对照组比较治疗效果。
我们的研究包括37例SSHL患者,他们在接受10天静脉类固醇一线治疗结束时,纯音4频率(0.5、1、2和4kHz)平均听阈(PTA)比30dB差或比健侧耳差10dB以上(定义为静脉治疗失败)。他们被随机分为两组,治疗组和对照组。治疗组的19例患者通过直接注射接受了浓度为80mg/2mL的约0.5mL醋酸甲泼尼龙无菌水混悬液。该操作在15天内进行4次。每次注射前及最后一次注射后约1.5个月进行听力图检查。
所有患者对该操作耐受性良好。在最后一次就诊时,所有患者均未发现鼓膜穿孔或感染。对于接受鼓室内治疗的19例患者,9例患者的PTA阈值改善超过10dB,10例患者的变化不超过10dB,且无患者恶化超过10dB。在对照组中,没有患者的变化超过10dB。差异具有统计学意义(P = 0.002)。治疗组的平均PTA改善了14.9dB,而对照组恶化了0.8dB,这一差异也具有统计学意义(P = 0.0005)。鼓室内治疗(P = 0.0001)、静脉注射后较好的PTA(P = 0.0008)以及无眩晕(P = 0.02)是预后的良好预测指标。相比之下,性别、年龄、患耳、入院天数以及初始听力图模式对预后无显著影响。
静脉类固醇治疗失败后鼓室内注射类固醇是突发性感音神经性听力损失的一种安全有效的治疗方法。